Jeppe Friborg

Dr. Jeppe Friborg


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in The Lancet Oncology
Verified
Journal Article
Closed access
BOBrian O’Sullivan
Brian O’Sullivan
SHShao Hui Huang
Shao Hui Huang
JSJie Su
Jie Su
AGAdam S Garden
Adam S Garden
ESErich M Sturgis
Erich M Sturgis
WXWei Xu
Wei Xu

1 June 2017 in European Journal of Cancer
Verified
Journal Article
Closed access
SMSanne Høxbroe Michaelsen
Sanne Høxbroe Michaelsen
CGChristian Gronhoj
Christian Gronhoj
JMJacob Høxbroe Michaelsen
Jacob Høxbroe Michaelsen
JFJeppe Friborg
Jeppe Friborg
Christian von BuchwaldChristian von Buchwald
Christian von Buchwald

10 April 2019 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
JRJacob H. Rasmussen
Jacob H. Rasmussen
GLGiedrius Lelkaitis
Giedrius Lelkaitis
KHKatrin Håkansson
Katrin Håkansson
IVIvan R. Vogelius
Ivan R. Vogelius
HJHelle H. Johannesen
Helle H. Johannesen
JFJeppe Friborg
Jeppe Friborg
Intratumor heterogeneity may contribute to the ambiguous clinical results on PD-L1 status as a predictor for immunotherapy response in patients with HNSCC. This decreases the utility of PD-L1 expression from single tumour biopsies as a predictive biomarker. In this prospective study, intratumor heterogeneity of PD-L1 expression in HNSCC was investigated with both Tumour Proportion Score (TPS) and Combined Positive Score (CPS). Thirty-three whole surgical specimens from 28 patients with HNSCC were included. PD-L1 expression in six random core biopsies from each surgical specimen was used to assess the concordance between multiple biopsies and the negative predictive value of a single negative core biopsy. With 1% cut off, 36% of the specimens were concordant with TPS and 52% with CPS. With a 50% cut-off value the concordance was 70% with TPS and 55% with CPS. Defining a tumour as positive if just a single-one of the biopsies was positive, the negative predictive value (NPV) of a single negative core biopsy was 38.9 and 0% (1% cut off), and 79.9% and 62.8% (50% cut off) for TPS and CPS, respectively. In conclusion, PD-L1 positivity varies markedly within the tumour, both with TPS and CPS, challenging the utility of this biomarker.

1 September 2008 in The Lancet Oncology
Verified
Journal Article
Closed access
JFJeppe Friborg
Jeppe Friborg
MMMads Melbye
Mads Melbye

16 August 2007
Verified
Book Chapter
Closed access
HHHenrik Hjalgrim
Henrik Hjalgrim
JFJeppe Friborg
Jeppe Friborg
MMMads Melbye
Mads Melbye
EPSTEIN-BARR VIRUS EPIDEMIOLOGY Epidemiology of primary Epstein-Barr virus infection Epstein-Barr virus (EBV) is an ancient virus, and has probably coevolved with its different hosts over the last 90–100 million years (McGeoch et al., 1995). With the ability to establish lifelong latency and intermittent reactivation after primary infection and with limited clinical symptoms in the majority of infected individuals, EBV has become ubiquitous in all human populations Age at primary infection Children in developing countries acquire the infection in the first few years of life, and universal seroconversion is often seen by ages 3–4 years, whereas infection in developed countries often is delayed until adolescence (de The et al., 1975; Haahr et al., 2004; Henle and Henle, 1967; Melbye et al., 1984a,b) (Figure 53.1). In some developed countries a bimodal infection rate, with peaks in children below 5 years and again after 10 years of age, has been described (Edwards and Woodroof, 1979; Henle and Henle, 1967; Lai et al., 1975). Oral EBV excretion between parents and infants, and from intimate partners in adolescence and early adulthood is the likely explanation for the observed bimodality (Crawford et al., 2002; Fleisher et al., 1979). EBV antibody titers in seropositive individuals vary according to age following a U-shaped pattern, with high titers among infants and in the elderly (above 50 years) (Glaser et al., 1985; Venkitaraman et al., 1985).

21 February 2007 in Cancer
Verified
Journal Article
Closed access
PDF file
JFJeppe Friborg
Jeppe Friborg
Jian-Min YuanJian-Min Yuan
Jian-Min Yuan
RWRenwei Wang
Renwei Wang
WKWoon‐Puay Koh
Woon‐Puay Koh
HLHin‐Peng Lee
Hin‐Peng Lee
MYMimi C. Yu
Mimi C. Yu